Relevance of infection with human papillomavirus: The role of the p53 tumor suppressor protein and E6/E7 zinc finger proteins (Review)

International Journal of Oncology

Volumn 43, Issue 6, 2013, Pages 1754-1762

  Ruttkay nedecky, Branislav ^a,b   Jimenez Jimenez, Ana Maria ^a,b   Nejdl, Lukas ^a   Chudobova, Dagmar ^a   Gumulec, Jaromir ^b,c   Masarik, Michal ^b,c   Adam, Vojtech ^a,b   Kizek, Rene ^a,b  

^a MENDEL UNIVERSITY IN BRNO   (Czech Republic)

^b BRNO UNIVERSITY OF TECHNOLOGY   (Czech Republic)

^c MASARYK UNIVERSITY   (Czech Republic)

Author keywords

Head and neck cancer; Human papillomavirus; Metallothionein; Protein p53; Zinc finger proteins

Indexed keywords

METALLOTHIONEIN; PROTEIN E6; PROTEIN E7; PROTEIN P53; ZINC; ZINC FINGER PROTEIN;

CARCINOGENESIS; GENE THERAPY; HEAD AND NECK CANCER; HUMAN; LARYNX CARCINOMA; LIP CANCER; MOUTH CARCINOMA; NOSE CAVITY CANCER; PAPILLOMAVIRUS INFECTION; PARANASAL SINUS CANCER; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; SALIVARY GLAND CANCER; UTERINE CERVIX CARCINOMA; VIROLOGY; WART VIRUS;

CELL TRANSFORMATION, NEOPLASTIC; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; METALLOTHIONEIN; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; PROTEIN-TYROSINE KINASES; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; UTERINE CERVICAL NEOPLASMS; ZINC FINGERS;

EID: 84891916240     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2013.2105     Document Type: Review

References (110)

1. Stanley M: Pathology and epidemiology of HPV infection in females. Gynecol Oncol 117: S5-S10, 2010.
2. Lowy DR, Strickland JE and Yuspa SH: Efficient induction of papillomas by Harvey murine sarcoma-virus. Clin Res 34: A764, 1986.
3. Joh J, Jenson AB, Proctor M, et al: Molecular diagnosis of a laboratory mouse papillomavirus (MusPV). Exp Mol Pathol 93: 416-421, 2012.
4. Mitsouras K, Faulhaber EA, Hui G, et al: Development of a PCR assay to detect papillomavirus infection in the snow leopard. BMC Vet Res 7: 1-11, 2011.
5. Badulescu F, Crisan A, Badulescu A and Schenker M: Recent data about the role of human papillomavirus (HPV) in oncogenesis of head and neck cancer. Rom J Morphol Embryol 51: 437-440, 2010.
6. Fakhry C, Westra WH, Cmelak SLA, et al: Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100: 261-269, 2008.
7. Syrjanen S: Human papillomavirus (HPV) in head and neck cancer. J Clin Virol 32: S59-S66, 2005.
8. Walden MJ and Aygun N: Head and neck cancer. Semin Roentgenol 48: 75-86, 2013.
9. Forte T, Niu J, Lockwood GA and Bryant HE: Incidence trends in head and neck cancers and human papillomavirus (HPV)-associated oropharyngeal cancer in Canada, 1992-2009. Cancer Causes Control 23: 1343-1348, 2012.
10. Axell T, Pindborg JJ, Smith CJ and van der Waal I: Oral white lesions with special reference to precancerous and tobacco related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18-21 1994. J Oral Pathol Med 25: 49-54, 1996.
11. Janicek MF and Averette HE: Cervical cancer: prevention, diagnosis, and therapeutics. CA Cancer J Clin 51: 92-114, 2001.
12. Chen YC and Hunter DJ: Molecular epidemiology of cancer. CA Cancer J Clin 55: 45-54, 2005.
13. De Villiers EM, Fauquet C, Broker TR, Bernard HU and zur Hausen H: Classification of papillomaviruses. Virology 324: 17-27, 2004.
14. Bernard HU, Burk RD, Chen ZG, van Doorslaer K, zur Hausen H and de Villiers EM: Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 401: 70-79, 2010.
15. Doorbar J, Quint W, Banks L, et al: The biology and life-cycle of human papillomaviruses. Vaccine 30: F55-F70, 2012.
16. Chen RW, Aaltonen LM and Vaheri A: Human papillomavirus type 16 in head and neck carcinogenesis. Rev Med Virol 15: 351-363, 2005.
17. Pfister H: HPV and skin neoplasia. Hautarzt 59: 26-30, 2008 (In German).
18. Steben M and Duarte-Franco E: Human papillomavirus infection: epidemiology and pathophysiology. Gynecol Oncol 107: S2-S5, 2007.
19. Chang KC, Su IJ, Tsai ST, Shieh DB and Jin YT: Pathological features of betel quid-related oral epithelial lesions in Taiwan with special emphasis on the tumor progression and human papillomavirus association. Oncology 63: 362-369, 2002.
20. Kero K, Rautava J, Syrjanen K, Grenman S and Syrjanen S: Oral mucosa as a reservoir of human papillomavirus: point prevalence, genotype distribution, and incident infections among males in a 7-year prospective study. Eur Urol 62: 1063-1070, 2012.
21. Hong AM, Martin A, Armstrong BK, et al: Human papillomavirus modifies the prognostic significance of T stage and possibly N stage in tonsillar cancer. Ann Oncol 24: 215-219, 2013.
22. Milano MT, Peterson CR, Zhang H, Singh DP and Chen Y: Second primary lung cancer after head and neck squamous cell cancer: population-based study of risk factors. Head Neck 34: 1782-1788, 2012.
23. Ragin CCR and Taioli E: Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 121: 1813-1820, 2007.
24. Lin KY, Westra WH, Kashima HK, Mounts P and Wu TC: Coinfection of HPV-11 and HPV-16 in a case of laryngeal squamous papillomas with severe dysplasia. Laryngoscope 107: 942-947, 1997.
25. Syrjanen KJ, Chang F and Syrjanen SM: HPV infections in etiology of benign and malignant sinonasal, bronchial and oesophageal squamous cell lesions. In: Eurogin 2000: 4th International Multidisciplinary Congress. Monsonego J (ed). Medimond S R L: 40128 Bologna, pp169-179, 2000.
26. Hoffmann M, Klose N, Gottschlich S, et al: Detection of human papillomavirus DNA in benign and malignant sinonasal neoplasms. Cancer Lett 239: 64-70, 2006.
27. Syrjanen S: Human papillomavirus infections and oral tumors. Med Microbiol Immunol 192: 123-128, 2003.
28. Kashima HK, Kessis T, Hruban RH, Wu TC, Zinreich SJ and Shah KV: Human papilloma virus in sinonasal papillomas and squamous-cell carcinoma. Laryngoscope 102: 973-976, 1992.
29. Mansell NJ and Bates GJ: The inverted Schneiderian papilloma: a review and literature report of 43 new cases. Rhinology 38: 97-101, 2000.
30. Zandberg DP, Bhargava R, Badin S and Cullen KJ: The role of human papillomavirus in nongenital cancers. CA Cancer J Clin 63: 57-81, 2013.
31. Ustav M, Ustav E, Szymanski P and Stenlund A: Identification of the origin of replication of bovine papillomavirus and characterization of the viral origin recognition factor-E1. EMBO J 10: 4321-4329, 1991.
32. Baker CC, Phelps WC, Lindgren V, Braun MJ, Gonda MA and Howley PM: Structural and transcriptional analysis of human papillomavirus type-16 sequences in cervical-carcinoma cell-lines. J Virol 61: 962-971, 1987.
33. Bouvard V, Storey A, Pim D and Banks L: Characterization of the human papillomavirus E2 protein - evidence of transactivation and transrepression in cervical keratinocytes. EMBO J 13: 5451-5459, 1994.
34. Foguel D, Silva JL and de Prat-Gay G: Characterization of a partially folded monomer of the DNA-binding domain of human papillomavirus E2 protein obtained at high pressure. J Biol Chem 273: 9050-9057, 1998.
35. Zur Hausen H: Cervical carcinoma and human papillomavirus: on the road to preventing a major human cancer. J Natl Cancer Inst 93: 252-253, 2001.
36. Barbosa MS, Lowy DR and Schiller JT: Papillomavirus polypeptide-E6 and polypeptide-E7 are zinc-binding proteins. J Virol 63: 1404-1407, 1989.
37. Scheffner M, Werness BA, Huibregtse JM, Levine AJ and Howley PM: The E6 oncoprotein encoded by human papillomavirus type-16 and type-18 promotes the degradation of P53. Cell 63: 1129-1136, 1990.
38. Vega-Pena A, Illades-Aguiar B, Flores-Alfaro E, Lopez-Bayghen E, Reyes-Maldonado E and Alarcon-Romero LD: Correlation between KI-67 and telomerase expression with in situ hybridization for high-risk human papillomavirus. Arch Biol Sci 65: 81-90, 2013.
39. Li DS, Dong BL, Hu ZM, et al: A combined assay of hTERT and E6 oncoprotein to identify virus-infected keratinocytes with higher telomerase activity in human papillomaviruses 16 and 18-related bowenoid papulosis. Am J Dermatopathol 34: 813-817, 2012.
40. Zhao YX, Qi L, Chen F, Zhao Y and Fan CH: Highly sensitive detection of telomerase activity in tumor cells by cascade isothermal signal amplification based on three-way junction and base-stacking hybridization. Biosens Bioelectron 41: 764-770, 2013.
41. Wilting SM, Verlaat W, Jaspers A, et al: Methylation-mediated transcriptional repression of microRNAs during cervical carcinogenesis. Epigenetics 8: 220-228, 2013.
42. Dayyani F, Etzel CJ, Liu M, Ho CH, Lippman SM and Tsao AS: Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC). Head Neck Oncol 2: 1-11, 2010.
43. Dyson N, Howley PM, Munger K and Harlow E: The human papilloma virus-16 E7-oncoprotein is able to bind to the retinoblastoma gene-product. Science 243: 934-937, 1989.
44. Strati K, Pitot HC and Lambert PF: Identification of biomarkers that distinguish human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers in a mouse model. Proc Natl Acad Sci USA 103: 14152-14157, 2006.
45. Smith EM, Pawlita M, Rubenstein LM, Haugen TH, Hamsikova E and Turek LP: Risk factors and survival by HPV-16 E6 and E7 antibody status in human papillomavirus positive head and neck cancer. Int J Cancer 127: 111-117, 2010.
46. Doorbar J and Gallimore PH: Identification of proteins encoded by the L1 and L2 open reading frames of human papillomavirus 1a. J Virol 61: 2793-2799, 1987.
47. Rose BR, Thompson CH, Tattersall MH, O'Brien CJ and Cossart YE: Squamous carcinoma of the head and neck: molecular mechanisms and potential biomarkers. Aust N Z J Surg 70: 601-606, 2000.
48. Wiest T, Schwarz E, Enders C, Flechtenmacher C and Bosch FX: Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 21: 1510-1517, 2002.
49. Bedell MA, Jones KH and Laimins LA: The E6-E7 region of human papillomavirus type-18 is sufficient for transformation of NIH-3T3 and RAT-1 cells. J Virol 61: 3635-3640, 1987.
50. Choo KB, Pan CC and Han SH: Integration of human papillomavirus type-16 into cellular DNA of cervical-carcinoma-preferential deletion of the E2 gene and invariable retention of the long control region and the E6/E7 open reading frames. Virology 161: 259-261, 1987.
51. Huibregtse JM, Scheffner M and Howley PM: Cloning and expression of the cDNA for E6-AP, a protein that mediates the interaction of the human papillomavirus E6 oncoprotein with P53. Mol Cell Biol 13: 775-784, 1993.
52. Chellappan S, Kraus VB, Kroger B, et al: Adenovirus-E1A, simian virus-40 tumor-antigen, and human papillomavirus-E7 protein share the capacity to disrupt the interaction between transcription factor-E2F and the retinoblastoma gene-product. Proc Natl Acad Sci USA 89: 4549-4553, 1992.
53. Cobrinik D, Dowdy SF, Hinds PW, Mittnacht S and Weinberg RA: The retinoblastoma protein and the regulation of cell cycling. Trends Biochem Sci 17: 312-315, 1992.
54. Nevins JR: E2F - a link between the Rb tumor suppressor protein and viral oncoproteins. Science 258: 424-429, 1992.
55. Gillison ML, Koch WM, Capone RB, et al: Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92: 709-720, 2000.
56. May P and May E: Twenty years of p53 research: structural and functional aspects of the p53 protein. Oncogene 18: 7621-7636, 1999.
57. Yu ZK, Geyer RK and Maki CG: MDM2-dependent ubiquitination of nuclear and cytoplasmic P53. Oncogene 19: 5892-5897, 2000.
58. Haupt Y, Maya R, Kazaz A and Oren M: Mdm2 promotes the rapid degradation of p53. Nature 387: 296-299, 1997.
59. Huibregtse JM, Scheffner M and Howley PM: A cellular protein mediates association of P53 with the E6 oncoprotein of human papillomavirus type-16 or type-18. EMBO J 10: 4129-4135, 1991.
60. Chen JJ, Hong YH, Rustamzadeh E, Baleja JD and Androphy EJ: Identification of an alpha helical motif sufficient for association with papillomavirus E6. J Biol Chem 273: 13537-13544, 1998.
61. Elston RC, Napthine S and Doorbar J: The identification of a conserved binding motif within human papillomavirus type 16 E6 binding peptides, E6AP and E6BP. J Gen Virol 79: 371-374, 1998.
62. Huibregtse JM, Scheffner M and Howley PM: Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with P53, and ubiquitination of associated proteins Mol Cell Biol 13: 4918-4927, 1993.
63. Yu Y, Yang AM, Hu SK, Zhang JH and Yan H: Significance of human papillomavirus 16/18 infection in association with p53 mutation in lung carcinomas. Clin Respir J 7: 27-33, 2013.
64. Katori H, Nozawa A and Tsukuda M: Relationship between p21 and p53 expression, human papilloma virus infection and malignant transformation in sinonasal-inverted papilloma. Clin Oncol 18: 300-305, 2006.
65. Fujita S, Senba M, Kumatori A, Hayashi T, Ikeda T and Toriyama K: Human papillomavirus infection in oral verrucous carcinoma: genotyping analysis and inverse correlation with p53 expression. Pathobiology 75: 257-264, 2008.
66. Reschner A, Bontems S, Le Gac S, et al: Ruthenium oligonucleotides, targeting HPV16 E6 oncogene, inhibit the growth of cervical cancer cells under illumination by a mechanism involving p53. Gene Ther 20: 435-443, 2013.
67. Togtema M, Pichardo S, Jackson R, Lambert PF, Curiel L and Zehbe I: Sonoporation delivery of monoclonal antibodies against human papillomavirus 16 E6 restores p53 expression in transformed cervical keratinocytes. PLoS One 7: 1-12, 2012.
68. Habbous S, Pang V, Eng L, et al: p53 Arg72Pro polymorphism, HPV status and initiation, progression, and development of cervical cancer: a systematic review and meta-analysis. Clin Cancer Res 18: 6407-6415, 2012.
69. Chen SP, Hsu NY, Wu JY, et al: Association of p53 codon 72 genotypes and clinical outcome in human papillomavirus-infected lung cancer patients. Ann Thorac Surg 95: 1196-1203, 2013.
70. Grossman SR and Laimins LA: E6-protein of human papillomavirus type-18 binds zinc. Oncogene 4: 1089-1093, 1989.
71. Kanda T, Watanabe S, Zanma S, Sato H, Furuno A and Yoshiike K: Human papillomavirus type-16 E6 proteins with glycine substitution for cysteine in the metal-binding motif. Virology 185: 536-543, 1991.
72. Beerheide W, Bernard HU, Tan YJ, Ganesan A, Rice WG and Ting AE: Potential drugs against cervical cancer: zinc-ejecting inhibitors of the human papillomavirus type 16 E6 oncoprotein. J Natl Cancer Inst 91: 1211-1220, 1999.
73. Chan SY, Delius H, Halpern AL and Bernard HU: Analysis of genomic sequences of 95 papillomavirus types - uniting typing, phylogeny, and taxonomy. J Virol 69: 3074-3083, 1995.
74. Ullman CG, Haris PI, Galloway DA, Emery VC and Perkins SJ: Predicted alpha-helix/beta-sheet secondary structures for the zinc-binding motifs of human papillomavirus E7 and E6 proteins by consensus prediction averaging and spectroscopic studies of E7. Biochem J 319: 229-239, 1996.
75. Griffin H, Elston R, Jackson D, et al: Inhibition of papillomavirus protein function in cervical cancer cells by intrabody targeting. J Mol Biol 355: 360-378, 2006.
76. Zimmermann H, Degenkolbe R, Bernard HU and O'Connor MJ: The human papillomavirus type 16 E6 oncoprotein can downregulate p53 activity by targeting the transcriptional coactivator CBP/p300. J Virol 73: 6209-6219, 1999.
77. Jong JE, Jeong KW, Shin H, Hwang LR, Lee D and Seo T: Human papillomavirus type 16 E6 protein inhibits DNA fragmentation via interaction with DNA fragmentation factor 40. Cancer Lett 324: 109-117, 2012.
78. Mavromatis KO, Jones DL, Mukherjee R, Yee C, Grace M and Munger K: The carboxyl-terminal zinc-binding domain of the human papillomavirus E7 protein can be functionally replaced by the homologous sequences of the E6 protein. Virus Res 52: 109-118, 1997.
79. Wayengera M: Zinc finger arrays binding human papillomavirus types 16 and 18 genomic DNA: precursors of gene-therapeutics for in-situ reversal of associated cervical neoplasia. Theor Biol Med Model 9: 1-13, 2012.
80. Cannavo I, Benchetrit M, Loubatier C, Michel G, Lemichez E and Giordanengo V: Characterization of a cluster of oncogenic mutations in E6 of a human papillomavirus 83 variant isolated from a high-grade squamous intraepithelial lesion. J Gen Virol 92: 2428-2436, 2011.
81. Avvakumov N, Torchia J and Mymryk JS: Interaction of the HPV E7 proteins with the pCAF acetyltransferase. Oncogene 22: 3833-3841, 2003.
82. Mino T, Mori T, Aoyama Y and Sera T: Cell-permeable artificial zinc-finger proteins as potent antiviral drugs for human papillomaviruses. Arch Virol 153: 1291-1298, 2008.
83. Olthof NC, Straetmans J, Snoeck R, Ramaekers FCS, Kremer B and Speel EJM: Next-generation treatment strategies for human papillomavirus-related head and neck squamous cell carcinoma: where do we go? Rev Med Virol 22: 88-105, 2012.
84. Garcia-Vallve S, Alonso A and Bravo IG: Papillomaviruses: different genes have different histories. Trends Microbiol 13: 514-521, 2005.
85. Van Doorslaer K, Sidi A, Zanier K, et al: Identification of unusual E6 and E7 proteins within avian papillomaviruses: cellular localization, biophysical characterization, and phylogenetic analysis. J Virol 83: 8759-8770, 2009.
86. Cole ST and Danos O: Nucleotide-sequence and comparative-analysis of the human papillomavirus type 18 genome. Phylogeny of papillomaviruses and repeated structure of the E6 and E7 gene products. J Mol Biol 193: 599-608, 1987.
87. Gammoh N, Grm HS, Massimi P and Banks L: Regulation of human papillomavirus type 16 E7 activity through direct protein interaction with the E2 transcriptional activator. J Virol 80: 1787-1797, 2006.
88. Ruttkay-Nedecky B, Nejdl L, Gumulec J, et al: The role of metallothionein in oxidative stress. Int J Mol Sci 14: 6044-6066, 2013.
89. Krizkova S, Ryvolova M, Hrabeta J, et al: Metallothioneins and zinc in cancer diagnosis and therapy. Drug Metab Rev 44: 287-301, 2012.
90. Eckschlager T, Adam V, Hrabeta J, Figova K and Kizek R: Metallothioneins and cancer. Curr Protein Pept Sci 10: 360-375, 2009.
91. Krizkova S, Fabrik I, Adam V, Hrabeta J, Eckschlager T and Kizek R: Metallothionein - a promising tool for cancer diagnostics. Bratisl Lek Listy 110: 93-97, 2009.
92. Babula P, Masarik M, Adam V, et al: Mammalians' metallothioneins and their properties and functions. Metallomics 4: 739-750, 2012.
93. Krejcova L, Fabrik I, Hynek D, et al: Metallothionein electrochemically determined using Brdicka reaction as a promising blood marker of head and neck malignant tumours. Int J Electrochem Sci 7: 1767-1784, 2012.
94. Sochor J, Hynek D, Krejcova L, et al: Study of metallothionein role in spinocellular carcinoma tissues of head and neck tumours using Brdicka reaction. Int J Electrochem Sci 7: 2136-2152, 2012.
95. Masarik M, Cernei N, Majzlik P, et al: Level of metallothionein, glutathione and heat-stable proteins in tumours from patients with head and neck cancer. Int J Mol Med 26: S46, 2010.
96. Dutsch-Wicherek M, Lazar A, Tomaszewska R, Kazmierczak W and Wicherek L: Analysis of metallothionein and vimentin immunoreactivity in pharyngeal squamous cell carcinoma and its microenvironment. Cell Tissue Res 352: 341-349, 2013.
97. Jayasurya A, Bay BH, Yap WM, Tan NG and Tan BKH: Proliferative potential in nasopharyngeal carcinoma: correlations with metallothionein expression and tissue zinc levels. Carcinogenesis 21: 1809-1812, 2000.
98. Dutsch-Wicherek M, Popiela TJ, Klimek M, et al: Metallothionein stroma reaction in tumor adjacent healthy tissue in head and neck squamous cell carcinoma and breast adenocarcinoma. Neuroendocrinol Lett 26: 567-574, 2005.
99. Babula P, Kohoutkova V, Opatrilova R, Dankova I, Masarik M and Kizek R: Pharmaceutical importance of zinc and metallothionein in cell signalling. Chim Oggi-Chem Today 28: 18-21, 2010.
100. Gumulec J, Masarik M, Krizkova S, et al: Insight to physiology and pathology of zinc(II) ions and their actions in breast and prostate carcinoma. Curr Med Chem 18: 5041-5051, 2011.
101. Meplan C, Richard MJ and Hainaut P: Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells. Oncogene 19: 5227-5236, 2000.
102. Hainaut P and Mann K: Zinc binding and redox control of p53 structure and function. Antioxid Redox Signal 3: 611-623, 2001.
103. Pintus SS, Ivanisenko NV, Demenkov PS, et al: The substitutions G245C and G245D in the Zn2+-binding pocket of the p53 protein result in differences of conformational flexibility of the DNA-binding domain. J Biomol Struct Dyn 31: 78-86, 2013.
104. Tohyama C, Suzuki JS, Hemelraad J, Nishimura N and Nishimura H: Induction of metallothionein and its localization in the nucleus of rat hepatocytes after partial-hepatectomy. Hepatology 18: 1193-1201, 1993.
105. Tsujikawa K, Imai T, Kakutani M, et al: Localization of metallothionein in nuclei of growing primary cultured adult-rat hepatocytes. FEBS Lett 283: 239-242, 1991.
106. Nartey NO, Banerjee D and Cherian MG: Immunohistochemical localization of metallothionein in cell-nucleus and cytoplasm of fetal human-liver and kidney and its changes during development. Pathology 19: 233-238, 1987.
107. Banerjee D, Onosaka S and Cherian MG: Immunohistochemical localization of metallothionein in cell-nucleus and cytoplasm of rat-liver and kidney. Toxicology 24: 95-105, 1982.
108. Tohno Y, Tohno S, Minami T, et al: Bindings of metallothionein to supranucleosomal fibers in mouse pancreatic nuclei after induction by 4-aminopyrazolo [3,4-d] pyrimidine. Cell Mol Biol 42: 1121-1127, 1996.
109. 2+-induction of metallothionein in myotomal cell nuclei during somitogenesis of Xenopus laevis. Mol Reprod Dev 43: 444-451, 1996.
110. Bernard X, Robinson P, Nomine Y, et al: Proteasomal degradation of p53 by human papillomavirus E6 oncoprotein relies on the structural integrity of p53 core domain. PLoS One 6: 1-10, 2011.